HONG KONG – Nagoya, Japan-based Askat Inc. has signed a $1.2 billion licensing deal for two of its immune-oncology compounds with Arrys Therapeutics Inc., of Cambridge, Mass. Arrys was granted research, development and marketing rights for Askat's two prostaglandin E2 receptor 4 (EP4) antagonists, AAT-007 and AAT-008, in the global market excluding China.